Interest in nanotechnology, including both polymeric and lipidic nanoparticles, has grown significantly in the last decade. The tremendous success of mRNA-lipid nanoparticle (LNP)-based vaccines during the COVID-19 pandemic has led to further explosive growth in development and created new opportunities in this area. The unprecedented speed of development of the COVID-19 LNP-based vaccines was, to a large extent, built upon foundational work performed over the last 10–15 years in LNP platform development.

In this collaborative webinar, experts Dr Julia Rashba-Step, Dr Cate O’Brien, Dr Nicholas Boylan and Dr Nicholas Karabin, shared their insights about the most important considerations when making liposomes and lipid nanoparticles (LNPs) with microfluidics.



Interested to learn more about liposomes and lipid nanoparticles?

Read more about how Microfluidic technology enables increased production control over the lipid’s/liposome’s physical properties, especially in terms of small mean size, narrow size distribution and lamellarity.


controlled synthesis of lipid nanoparticles

Further reading

Read our new Application Note on the controlled synthesis of lipid nanoparticles using the ANP System and learn about the research done by our Experts on the key parameters involved in tuning LNPs’ size, and a comparison between the protocol and continuous mode to demonstrate the transferability of the process parameters for bulk production of LNPs.

Download App Note

Are you looking to expand your LNP capabilities? Phosphorex has developed a comprehensive approach to optimize the LNP development process and streamline transition into clinical manufacturing.

See brochure

Have any questions for us?